[go: up one dir, main page]

EE200300093A - Spiroheterotsüklilised nitriilid, mis on kasulikud tsüsteiini proteaaside pöördinhibiitoritena - Google Patents

Spiroheterotsüklilised nitriilid, mis on kasulikud tsüsteiini proteaaside pöördinhibiitoritena

Info

Publication number
EE200300093A
EE200300093A EEP200300093A EEP200300093A EE200300093A EE 200300093 A EE200300093 A EE 200300093A EE P200300093 A EEP200300093 A EE P200300093A EE P200300093 A EEP200300093 A EE P200300093A EE 200300093 A EE200300093 A EE 200300093A
Authority
EE
Estonia
Prior art keywords
spiroheterocyclic
inhibitors
rotary
cysteine proteases
nitriles useful
Prior art date
Application number
EEP200300093A
Other languages
English (en)
Inventor
Bekkali Younes
R. Hickey Eugene
Liu Weimin
R. Patel Usha
M. Spero Denice
Sun Sanxing
S. Thomson David
D. Ward Yansey
R. Young Erick
Original Assignee
Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals, Inc. filed Critical Boehringer Ingelheim Pharmaceuticals, Inc.
Publication of EE200300093A publication Critical patent/EE200300093A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
EEP200300093A 2000-09-08 2001-03-14 Spiroheterotsüklilised nitriilid, mis on kasulikud tsüsteiini proteaaside pöördinhibiitoritena EE200300093A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/655,351 US6420364B1 (en) 1999-09-13 2000-09-08 Compound useful as reversible inhibitors of cysteine proteases
PCT/US2001/008084 WO2002020485A1 (en) 2000-09-08 2001-03-14 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases

Publications (1)

Publication Number Publication Date
EE200300093A true EE200300093A (et) 2005-02-15

Family

ID=24628539

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300093A EE200300093A (et) 2000-09-08 2001-03-14 Spiroheterotsüklilised nitriilid, mis on kasulikud tsüsteiini proteaaside pöördinhibiitoritena

Country Status (24)

Country Link
US (10) US6420364B1 (et)
EP (1) EP1322613A1 (et)
JP (1) JP2004508356A (et)
KR (1) KR20030051644A (et)
CN (1) CN1303067C (et)
AU (1) AU2001245694A1 (et)
BG (1) BG107585A (et)
BR (1) BR0113740A (et)
CA (1) CA2417177A1 (et)
CZ (1) CZ2003603A3 (et)
EA (1) EA005203B1 (et)
EE (1) EE200300093A (et)
HR (1) HRP20030163A2 (et)
HU (1) HUP0303934A2 (et)
IL (1) IL154080A0 (et)
MX (1) MXPA03001947A (et)
NO (1) NO20031065D0 (et)
NZ (1) NZ525169A (et)
PL (1) PL361038A1 (et)
SK (1) SK2862003A3 (et)
UA (1) UA73378C2 (et)
WO (1) WO2002020485A1 (et)
YU (1) YU17003A (et)
ZA (1) ZA200301032B (et)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
US7704958B1 (en) * 1999-03-05 2010-04-27 Bio Holding, Inc. Methods and compositions for inhibiting apoptosis using serine protease inhibitors
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6773704B1 (en) * 1999-10-28 2004-08-10 The Brigham And Women's Hospital, Inc. Methods of treating vascular disease associated with cystatin C deficiency
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2002069901A2 (en) * 2001-03-02 2002-09-12 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US6982263B2 (en) * 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005504078A (ja) 2001-09-14 2005-02-10 アベンティス・ファーマスーティカルズ・インコーポレイテツド カテプシン阻害剤としての新規化合物および組成物
EP1434769A2 (en) * 2001-10-02 2004-07-07 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
WO2003037892A1 (en) * 2001-10-29 2003-05-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
HUP0401906A3 (en) 2001-11-14 2008-07-28 Aventis Pharma Inc Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them
AU2003256305A1 (en) * 2002-06-24 2004-01-06 Axys Pharmaceuticals, Inc. Peptidic compounds as cysteine protease inhibitors
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US7326719B2 (en) * 2003-03-13 2008-02-05 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7465745B2 (en) * 2003-03-13 2008-12-16 Boehringer Ingelheim Pharmaceuticals, Inc. Cathepsin S inhibitors
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
WO2004089395A2 (en) * 2003-04-01 2004-10-21 Aventis Pharmaceuticals Inc. Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease
EP1761485A1 (en) * 2003-06-04 2007-03-14 Schering AG Amidino compounds as cysteine protease inhibitors
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
WO2005028429A2 (en) * 2003-09-18 2005-03-31 Axys Pharmaceuticals, Inc. Haloalkyl containing compounds as cysteine protease inhibitors
US7186827B2 (en) * 2003-10-30 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Dipeptide synthesis
AR046784A1 (es) * 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de amina ciclica composicion farmaceutica que lo comprende y su uso para preparar esta ultima
EP1694357A1 (en) * 2003-12-11 2006-08-30 Axys Pharmaceuticals, Inc. Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
CA2548600A1 (en) * 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US20070105892A1 (en) * 2003-12-23 2007-05-10 Axys Pharmaceuticals, Inc. Amidino compounds as cysteine protease inhibitors
EP1819667B1 (en) * 2004-12-02 2012-10-17 ViroBay, Inc. Sulfonamide compounds as cysteine protease inhibitors
EP1841730A4 (en) * 2005-01-19 2010-10-27 Merck Frosst Canada Ltd CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
HRP20130419T1 (en) 2005-03-21 2013-06-30 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
MX2007011739A (es) * 2005-03-22 2008-03-14 Celera Genomics Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
US7282964B2 (en) * 2005-05-25 2007-10-16 Texas Instruments Incorporated Circuit for detecting transitions on either of two signal lines referenced at different power supply levels
WO2006138265A2 (en) * 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067457B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
EP1951706A1 (en) * 2005-11-01 2008-08-06 Janssen Pharmaceutica N.V. Dihydroisoindolones as allosteric modulators of glucokinase
WO2007053499A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
NZ573049A (en) * 2006-06-01 2010-08-27 Sanofi Aventis Spirocyclic nitriles as protease inhibitors
US8652844B2 (en) 2006-06-13 2014-02-18 The Curators Of The University Of Missouri Methods for the cryopreservation of animal cells that contain high levels of intracellular lipids
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
DK2079683T3 (en) * 2006-10-04 2015-04-27 Virobay Inc Difluoro-containing compounds as cysteine protease inhibitors
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
KR100877394B1 (ko) 2007-07-11 2009-01-07 한국화학연구원 카보니트릴 화합물을 포함하는 골다공증 및 치은 질환의치료 및 예방을 위한 약제학적 조성물
WO2009011880A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
CA2693473A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
WO2009023193A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
MX2010006972A (es) 2007-12-21 2010-08-26 Ligand Pharm Inc Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
CN105574346A (zh) * 2008-09-05 2016-05-11 新基阿维罗米克斯研究公司 多肽偶联物与不可逆抑制剂的设计方法和检测方法
US20120088791A1 (en) * 2009-02-19 2012-04-12 Vanderbilt University Amidobipiperidinecarboxylate m1 allosteric agonists, analogs and derivatives thereof, and methods of making and using same
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
JP2013516422A (ja) 2009-12-30 2013-05-13 アビラ セラピューティクス， インコーポレイテッド タンパク質のリガンド−指向性共有的修飾
WO2012151319A1 (en) 2011-05-02 2012-11-08 Virobay, Inc. Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
EP2719693B1 (en) 2011-06-07 2016-08-10 Kureha Corporation Method for manufacturing oxetane compound, method for manufacturing azolylmethylcyclopentanol compound, and intermediate compound
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9187451B2 (en) 2011-11-18 2015-11-17 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
WO2014111113A1 (de) 2013-01-15 2014-07-24 Merck Patent Gmbh Acylguanidine zur behandlung von arthrose
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
EP3956309A4 (en) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. CRYSTALLINE FORMS AND METHODS FOR PRODUCING CRYSTALLINE FORMS OF A COMPOUND
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN111943848B (zh) * 2020-08-19 2023-05-05 苏州旺山旺水生物医药有限公司 一种elexacaftor中间体的制备方法及其应用

Family Cites Families (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
JPS4310619Y1 (et) 1967-02-16 1968-05-09
FI840260L (fi) 1983-01-27 1984-07-28 Ciba Geigy Ag Pyrrolidinonderivat och foerfarande foer deras framstaellning.
US4767202A (en) * 1984-01-20 1988-08-30 Minolta Camera Kabushiki Kaisha Objective lens system for optical recording type disks
EP0181351A4 (en) * 1984-05-09 1989-06-21 Univ Australian METHOD FOR MODULATING IMMUNE REACTION.
US4797202A (en) 1984-09-13 1989-01-10 The Dow Chemical Company Froth flotation method
US4737425A (en) * 1986-06-10 1988-04-12 International Business Machines Corporation Patterned resist and process
JPS6358346A (ja) 1986-08-29 1988-03-14 Fuji Photo Film Co Ltd カラ−写真現像液組成物及びハロゲン化銀写真感光材料の処理方法
US4734425A (en) 1986-10-17 1988-03-29 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs
US4749715A (en) 1987-03-02 1988-06-07 E. R. Squibb & Sons, Inc. 7-oxabicycloheptane substituted amino prostaglandin analogs
FR2615104B1 (fr) 1987-05-14 1989-08-18 Centre Nat Rech Scient Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme
JPS63301868A (ja) 1987-06-01 1988-12-08 Nippon Kayaku Co Ltd Ｎ−（２−クロロイソニコチノイル）アミノ酸誘導体およびそれを有効成分とする農園芸用殺菌剤
DE3719226A1 (de) 1987-06-09 1988-12-22 Bayer Ag (2-cyan-2-oximinoacetyl)-aminosaeure-derivate
US4971978A (en) 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
EP0389535A1 (en) 1987-10-26 1990-10-03 Warner-Lambert Company Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
US4957932A (en) 1987-11-25 1990-09-18 Merck Frosst Canada, Inc. Benzoheterazoles
US4962117A (en) 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US5004743A (en) 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
EP0336356A3 (en) 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
AU3570089A (en) 1988-05-03 1989-11-29 Upjohn Company, The Renin inhibitory peptides containing a substituted phenoxyacetyle group
DE3827727A1 (de) 1988-08-16 1990-02-22 Boehringer Ingelheim Kg Anellierte tetrahydropyridinessigsaeurederivate, verfahren zu deren herstellung und verwendung solcher verbindungen zur kardioprotektion
EP0374098A3 (de) 1988-12-15 1991-05-02 Ciba-Geigy Ag Retrovirale Proteasehemmer
US5270302A (en) 1988-12-21 1993-12-14 Abbott Laboratories Derivatives of tetrapeptides as CCK agonists
GB8909836D0 (en) 1989-04-28 1989-06-14 Boots Co Plc Therapeutic agent
DE3915755A1 (de) 1989-05-13 1990-11-29 Bayer Ag Fungizide mittel sowie substituierte aminosaeureamid-derivate und deren herstellung
US5504109A (en) 1989-05-13 1996-04-02 Bayer Aktiengesellschaft Susbstituted amino acid amide derivatives their preparation and use
US5196291A (en) 1989-05-24 1993-03-23 Fuji Photo Film Co., Ltd. Silver halide photographic material
JP2658004B2 (ja) 1989-05-31 1997-09-30 キヤノン株式会社 電子写真感光体
JPH0462788A (ja) 1990-06-30 1992-02-27 Toshiba Corp 電子レンジ
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH06145173A (ja) 1990-08-21 1994-05-24 Fujisawa Pharmaceut Co Ltd １−アザビシクロ［３．２．０］ヘプト−２−エン−２−カルボン酸化合物
JPH0511439A (ja) 1990-09-13 1993-01-22 Fuji Photo Film Co Ltd 光重合性組成物
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1992010675A1 (en) 1990-12-07 1992-06-25 Dyno Industrier A.S System for utilization of wave energy
DE4104257A1 (de) 1991-02-13 1992-08-20 Boehringer Ingelheim Kg Verwendung von anellierten tetrahydropyridinessigsaeurederivaten fuer die behandlung neurologischer erkrankungen
US5461176A (en) 1991-03-27 1995-10-24 The Du Pont Merck Pharmaceutical Company Processes for preparing bis-naphthalimides containing amino-acid derived linkers
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
US5190922A (en) 1991-06-04 1993-03-02 Abbott Laboratories Terminally modified tri-, tetra- and pentapeptide anaphylatoxin receptor ligands
JPH06510986A (ja) 1991-06-14 1994-12-08 カイロン　コーポレイション ピコルナウイルスプロテアーゼのインヒビター
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5298377A (en) 1991-08-28 1994-03-29 Eastman Kodak Company Photographic element with 2-equivalent magenta dye-forming coupler and filter dye
US5215876A (en) 1991-08-29 1993-06-01 Eastman Kodak Company Radiographic element with uv absorbation compound in polyester support
US5204349A (en) 1991-09-16 1993-04-20 Merck & Co., Inc. Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
JP2947539B2 (ja) 1991-11-12 1999-09-13 コニカ株式会社 ハロゲン化銀写真感光材料
KR100236806B1 (ko) 1991-12-10 2000-01-15 시오노 요시히코 방향족 설폰아미드계 하이드록삼산 유도체
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
GB9200209D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5218123A (en) 1992-02-18 1993-06-08 Warner-Lambert Company Didehydrotryptophan derivatives and pharmaceutical use thereof
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
JPH063787A (ja) 1992-06-18 1994-01-14 Konica Corp ハロゲン化銀写真感光材料用固形発色現像処理剤及び該固形発色現像処理剤を用いた処理方法
AU691468B2 (en) 1992-06-22 1998-05-14 Boehringer Ingelheim International Gmbh Ring-closed dihydropyridines and their use in the preparation of pharmaceutical compositions
FR2694006A1 (fr) 1992-07-22 1994-01-28 Esteve Labor Dr Amides dérivés de benzohétérocyles.
DE4225487A1 (de) 1992-07-30 1994-02-03 Schering Ag Interphenylen-bicyclo(3.3.0)octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JPH0651451A (ja) 1992-07-31 1994-02-25 Konica Corp ハロゲン化銀写真感光材料用固形処理剤
JP3168547B2 (ja) 1992-08-18 2001-05-21 日本製粉株式会社 ポテト生地用ミックス、ポテト生地の製造法およびポテト生地を用いたフライ食品
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
US5389682A (en) 1992-09-18 1995-02-14 Warner-Lambert Company Agents acting at cholecystokinin receptors
DE4232505A1 (de) 1992-09-29 1994-03-31 Degussa Verfahren zur Reduktion von Carbonsäuren oder Carbonsäurederivaten sowie neue Verbindungen
ES2150933T3 (es) 1992-12-22 2000-12-16 Lilly Co Eli Inhibidores de la proteasa vih utiles para el tratamiento del sida.
DE4303145A1 (de) 1993-01-30 1994-08-04 Schering Ag Interphenylen-2-Oxabicyclo(2.2.1)heptan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
US5677287A (en) 1993-03-18 1997-10-14 Pfizer Inc. Antibacterial 16-membered ring macrolides containing olefins at C-20
AU6697694A (en) 1993-03-29 1994-10-24 Du Pont Merck Pharmaceutical Company, The A process and intermediate compounds useful for the preparation of platelet glycoprotein IIb/IIIa inhibitors containing N alpha--methylarginine
JPH06340643A (ja) 1993-04-04 1994-12-13 Nippon Nohyaku Co Ltd オキサゾ−ル又はチアゾ−ル誘導体及びその製造方法並びに除草剤
JP3165760B2 (ja) 1993-04-12 2001-05-14 株式会社トクヤマ 新規化合物
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
WO1994025432A1 (fr) 1993-04-28 1994-11-10 Kumiai Chemical Industry Co., Ltd. Derive amide d'amino acide, bactericide horticole, et procede de production
JPH0789951A (ja) 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5514778A (en) 1993-07-01 1996-05-07 Eli Lilly And Company Anti-picornaviral agents
DE4321897A1 (de) 1993-07-01 1995-01-12 Hoechst Schering Agrevo Gmbh Substituierte Aminosäureamid-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung
DE4322067A1 (de) 1993-07-02 1995-01-12 Hoechst Schering Agrevo Gmbh Acylierte Aminophenylsulfonylharnstoffe; Darstellung und Verwendung als Herbizide und Wachstumsregulatoren
CH686479A5 (fr) 1993-08-11 1996-04-15 Nestle Sa Produit alimentaire a rehydratation rapide et son procede de preparation.
US5554753A (en) 1993-08-25 1996-09-10 Indiana University Foundation Catalytic enantioselective synthesis of α-amino acid derivatives by phase-transfer catalysis
JPH07101959A (ja) 1993-09-30 1995-04-18 Sankyo Co Ltd １−メチルカルバペネム誘導体
WO1995009838A1 (en) 1993-10-01 1995-04-13 Merrell Pharmaceuticals Inc. INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION
IT1270882B (it) 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
JP3075657B2 (ja) 1993-10-15 2000-08-14 富士写真フイルム株式会社 写真用処理組成物及び処理方法
US5780498A (en) 1993-11-01 1998-07-14 Ciba-Geigy Japan Limited Endothelin receptor antagonists
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
IL112759A0 (en) 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
US6143790A (en) 1994-03-10 2000-11-07 G.D. Searle & Co. L-N6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
DE59500620D1 (de) 1994-03-19 1997-10-16 Basf Ag Fungizide Carbamoyloximcarbonsäureamide
JPH07285931A (ja) 1994-04-19 1995-10-31 Tokuyama Corp 新規化合物
DE4415049A1 (de) 1994-04-29 1995-11-02 Hoechst Schering Agrevo Gmbh Acylierte Aminophenylsulfonylharnstoffe, Verfahren zu deren Herstellung und Verwendung als Herbizide und Wachstumsregulatoren
DE4419517A1 (de) 1994-06-03 1995-12-07 Basf Ag Substituierte 3-Phenylpyrazole
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
DE4431467A1 (de) 1994-09-03 1996-03-07 Basf Ag Caramoylcarbonsäureamide
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
SI0788498T1 (en) 1994-10-26 2001-12-31 Upjohn Co Phenyloxazolidinone antimicrobials
CA2163325A1 (en) 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
RU2154633C2 (ru) 1994-12-02 2000-08-20 Яманоути Фармасьютикал Ко., Лтд. Производные амидинонафтила и фармацевтическая композиция
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5691368A (en) 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
DE19501841A1 (de) 1995-01-23 1996-07-25 Bayer Ag Aminosäureamide
DE19505932B4 (de) 1995-02-21 2005-06-23 Degussa Ag Verfahren zur Herstellung von Oxazolidinonen, neue Oxazolidinone sowie Verwendung von Oxazolidinonen
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
JPH08248579A (ja) 1995-03-14 1996-09-27 Mitsubishi Paper Mills Ltd ハロゲン化銀写真感光材料及びその処理方法
KR19980703261A (ko) 1995-03-24 1998-10-15 다니엘 이이치. 페트리 가역성 프로테아제 억제제
US5776718A (en) * 1995-03-24 1998-07-07 Arris Pharmaceutical Corporation Reversible protease inhibitors
MY114302A (en) 1995-04-19 2002-09-30 Ihara Chemical Ind Co Benzylsulfide derivative, process for its production and pesticide
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5977075A (en) 1995-04-21 1999-11-02 Novartis Ag N-aroylamino acid amides as endothelin inhibitors
JPH08319291A (ja) 1995-05-25 1996-12-03 Meiji Seika Kaisha Ltd 新規セフェム誘導体
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ATE206702T1 (de) 1995-06-06 2001-10-15 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
WO1996040753A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis
JP2000501063A (ja) 1995-06-29 2000-02-02 メルク エンド カンパニー インコーポレーテッド ファルネシル−タンパク質トランスフェラーゼ阻害剤の組み合わせ
EP0838471A4 (en) 1995-07-07 2000-07-26 Sagami Chem Res PEPTIDE DERIVATIVES AND AGONISTS OF THE ANGIOTENSIN IV RECEPTOR
GB9518552D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New heterocyclic compounds
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
TW474946B (en) 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
BR9612435A (pt) 1995-12-29 1999-07-13 Boehringer Ingelheim Pharamceu Derivados de fenil tiazol com propreidades anti-herpes
AU1529997A (en) 1996-01-16 1997-08-11 Warner-Lambert Company Substituted histidine inhibitors of protein farnesyltransferase
AU1595997A (en) 1996-01-26 1997-08-20 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
US6288037B1 (en) 1996-01-29 2001-09-11 Basf Aktiengesellschaft Substrates and inhibitors for cysteine protease ICH-1
AU2277597A (en) 1996-02-23 1997-09-10 Ariad Pharmaceuticals, Inc. New inhibitors of sh2-mediated processes
DE19609955A1 (de) 1996-03-14 1997-09-18 Basf Ag Amidonitrile, Verfahren zu ihrer Herstellung, ihre Verwendung als Kaltbleichaktivatoren oder optische Aufheller in Wasch-, Reinigungs- und Bleichmitteln sowie ihre Verwendung als Ausgangsmaterial bei der Herstellung von Amidocarbonsäuren und Amidocarbonsäure-Derivaten
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
DE19621483A1 (de) 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621522A1 (de) 1996-05-29 1997-12-04 Hoechst Schering Agrevo Gmbh Neue N-Acylsulfonamide, neue Mischungen aus Herbiziden und Antidots und deren Verwendung
ATE212975T1 (de) 1996-05-31 2002-02-15 Carbamoylcarbonsäureamidoxime
DE19629717C1 (de) 1996-07-25 1998-02-12 Hoechst Ag Verfahren zur katalytischen Herstellung von N-Acylglycinderivaten
US5939527A (en) 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
CN1133649C (zh) 1996-10-18 2004-01-07 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3蛋白酶的抑制剂
EP0844248B1 (de) 1996-10-28 2002-07-10 Rolic AG Vernetzbare, photoaktive Silanderivate
AR010061A1 (es) 1996-11-12 2000-05-17 Garcia Cattebeke Cybele Carina Derivado de 3-(2-piridil)-pirazol substituidos, un proceso para su preparacion, compuestos intermediarios, una composicion herbicida e inhibidoradel crecimiento de plantas, un metodo para controlar e inhibir el crecimiento de las plantas y el uso de dicha composicion
ATE296797T1 (de) 1996-11-22 2005-06-15 Elan Pharm Inc N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
US5952322A (en) 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
DE69715038T2 (de) 1996-12-19 2003-03-13 Isagro S.P.A., Mailand/Milano Auf (n-phenylacetyl-n-2,6-xylyl)methylalaninat basierte fungizide zusammensetzungen
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
WO1998028269A1 (en) 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
HRP980093A2 (en) 1997-02-28 1998-12-31 Lilly Co Eli Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds
FR2762315B1 (fr) 1997-04-22 1999-05-28 Logeais Labor Jacques Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha
WO1998052941A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
WO1998052559A1 (en) 1997-05-23 1998-11-26 Bayer Corporation Raf kinase inhibitors
JP4344960B2 (ja) 1997-05-23 2009-10-14 バイエル、コーポレイション アリール尿素によるｐ３８キナーゼ活性の阻害
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EA200000048A1 (ru) 1997-06-19 2000-08-28 Дюпон Фармасьютикалз Компани ИНГИБИТОРЫ ФАКТОРА Ха, СОДЕРЖАЩИЕ ГРУППУ С НЕЙТРАЛЬНОЙ P1-СПЕЦИФИЧНОСТЬЮ
EP0897908A1 (de) 1997-08-19 1999-02-24 Roche Diagnostics GmbH 3-Aryl-Succinamido-Hydroxamsäuren, Prozesse zu ihrer Herstellung und diese Substanzen enthaltende Medikamente
JPH11100373A (ja) 1997-09-26 1999-04-13 Eisai Co Ltd 新規フェノチアジン誘導体及びその医薬
US5872122A (en) 1997-10-16 1999-02-16 Monsanto Company Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
TR200001179T2 (tr) 1997-10-31 2000-11-21 Aventis Pharma Ltd. Değiştirilmiş anilidler
JP4450988B2 (ja) 1997-11-05 2010-04-14 ノバルティス アーゲー ジペプチドニトリル
ES2155045T3 (es) 1997-12-22 2007-02-01 Bayer Pharmaceuticals Corp. Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
JP4437270B2 (ja) 1997-12-22 2010-03-24 バイエル コーポレイション 置換複素環式尿素を用いたｒａｆキナーゼの阻害
ATE298242T1 (de) 1998-05-05 2005-07-15 Warner Lambert Co Succinamid hemmstoffe des interleukin-1 beta konvertierenden enzyms
EP1076723A2 (en) 1998-06-04 2001-02-21 Reprogen, Inc. Use of cathepsin s in the diagnosis and treatment of endometriosis
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
YU66101A (sh) 1999-03-15 2004-07-15 Axys Pharmaceuticals Inc. Nova jedinjenja i kompozicije kao inhibitori proteaze
KR100430981B1 (ko) * 1999-08-10 2004-05-14 제이에프이 엔지니어링 가부시키가이샤 디프 드로잉성이 우수한 냉연강판의 제조방법
ES2199856T3 (es) * 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
KR100415718B1 (ko) * 1999-09-16 2004-01-24 제이에프이 엔지니어링 가부시키가이샤 고강도 박강판 및 그 제조방법
WO2001023625A1 (en) * 1999-09-29 2001-04-05 Nkk Corporation Sheet steel and method for producing sheet steel
CN1117880C (zh) * 1999-09-28 2003-08-13 日本钢管株式会社 高强度热轧钢板及其制造方法
WO2001023624A1 (fr) * 1999-09-29 2001-04-05 Nkk Corporation Tole d'acier et son procede de fabrication
CN1331183A (zh) 2000-06-28 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人dna修复蛋白10.23和编码这种多肽的多核苷酸

Also Published As

Publication number Publication date
US6420364B1 (en) 2002-07-16
ZA200301032B (en) 2004-04-21
US6858623B2 (en) 2005-02-22
BR0113740A (pt) 2003-06-24
US20030232826A1 (en) 2003-12-18
EP1322613A1 (en) 2003-07-02
WO2002020485A1 (en) 2002-03-14
US6525052B2 (en) 2003-02-25
US20040006078A1 (en) 2004-01-08
US7265132B2 (en) 2007-09-04
US6982272B2 (en) 2006-01-03
JP2004508356A (ja) 2004-03-18
CZ2003603A3 (cs) 2003-06-18
HRP20030163A2 (en) 2005-04-30
US20050032772A1 (en) 2005-02-10
US7056915B2 (en) 2006-06-06
MXPA03001947A (es) 2003-06-24
IL154080A0 (en) 2003-07-31
HUP0303934A2 (hu) 2004-04-28
SK2862003A3 (en) 2003-08-05
CA2417177A1 (en) 2002-03-14
KR20030051644A (ko) 2003-06-25
US7279472B2 (en) 2007-10-09
NO20031065L (no) 2003-03-07
YU17003A (sh) 2006-03-03
US20020137932A1 (en) 2002-09-26
BG107585A (bg) 2003-11-28
PL361038A1 (en) 2004-09-20
US6720319B2 (en) 2004-04-13
AU2001245694A1 (en) 2002-03-22
NO20031065D0 (no) 2003-03-07
US6787540B2 (en) 2004-09-07
UA73378C2 (en) 2005-07-15
EA005203B1 (ru) 2004-12-30
US6756372B2 (en) 2004-06-29
US20030225271A1 (en) 2003-12-04
CN1303067C (zh) 2007-03-07
NZ525169A (en) 2004-11-26
HK1060565A1 (en) 2004-08-13
US20030225270A1 (en) 2003-12-04
US20020058809A1 (en) 2002-05-16
US20030216383A1 (en) 2003-11-20
CN1471511A (zh) 2004-01-28
EA200300348A1 (ru) 2003-08-28
US20050032792A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
EE200300093A (et) Spiroheterotsüklilised nitriilid, mis on kasulikud tsüsteiini proteaaside pöördinhibiitoritena
EE200200132A (et) Uudsed spiroheterotsüklilised ühendid, mis on kasulikud tsüsteiinproteaaside pöörduvate inhibiitoritena
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
EP1272467A4 (en) Cathepsin cysteine protease inhibitors
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
NO20023780D0 (no) Dipeptid nitril katepsin K inhibitorer
DK1383731T3 (da) Biarylforbindelser som serinproteaseinhibitorer
NO20034044D0 (no) Metallproteinase-inhibitorer
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
NO20014483D0 (no) Aminderivater som proteaseinhibitorer
NO20031853D0 (no) Spiro-pyrimidin-2,4,6-trion metalloproteinase inhibitorer
DE60215623D1 (de) Breitspektrum 2-(substituierte-amino)-benzothiazol-sulfonamide hiv protease inhibitoren
ATE308325T1 (de) Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trion derivate als metalloproteinase inhibitoren
ATE429431T1 (de) 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren
MA25758A1 (fr) Inhibiteurs de protease.
ES1048791Y (es) Rodillo absorbente de impactos.
DK1217002T3 (da) 2-(4-pyridinyl)benzofuraner som metalloproteaseinhibitorer
NO20025005D0 (no) Proteaseinhibitorer
NO20032328L (no) Proteaseinhibitorer
NO20032290L (no) Nye forbindelser for anvendelse som HIV-protease-inhibitorer
EP1305019A4 (en) IMMUNOMODULATORY COMPOUNDS
SI1218372T1 (sl) Nove spiroheterociklične spojine, uporabne kot reverzibilni inhibitorji cisteinskih proteaz
NO20010900D0 (no) Oksamider som IMPDH-inhibitorer